How Much Does Belsomra (Suvorexant) Cost in Massachusetts in 2026?

Retail and Cash Prices Across Massachusetts

The sticker price for Belsomra rarely reflects what patients actually pay. Merck lists suvorexant at $340 per month for a 30-tablet supply, but cash-pay prices at Massachusetts retail pharmacies average roughly $85 per month in 2026. That gap exists because pharmacy benefit managers negotiate rebates that filter down to point-of-sale pricing at chains like CVS, Walgreens, and independent pharmacies across the state.

Prices vary by location. A CVS in downtown Boston may quote a different cash price than a Rite Aid in Springfield or a Costco pharmacy in Worcester. Checking GoodRx or RxSaver before filling can expose these differences. Some warehouse pharmacies (Costco, for example) price controlled substances lower than chain competitors even without a membership for pharmacy purchases.

Suvorexant is a Schedule IV controlled substance under DEA classification, which limits some discount mechanisms available for non-scheduled medications. Mail-order pharmacies licensed in Massachusetts can fill Schedule IV prescriptions, often at a lower per-unit cost for 90-day supplies. The FDA-approved labeling for Belsomra specifies doses of 5 mg, 10 mg, 15 mg, and 20 mg, all priced identically per tablet regardless of strength [1].

Massachusetts Medicaid (MassHealth) Coverage

MassHealth covers Belsomra, but you will need prior authorization. The PA requirement exists because MassHealth's preferred drug list places older, less expensive insomnia treatments (like generic zolpidem and trazodone) ahead of orexin receptor antagonists.

To obtain approval, prescribers typically must document that the patient tried and failed at least one preferred agent. A 2014 trial published in The Lancet Neurology (N=250 per arm) showed that suvorexant 40 mg and 20 mg improved subjective total sleep time by 22 and 25 minutes versus placebo over four weeks, with next-day somnolence as the most common adverse event at 11% versus 3% for placebo [2]. Citing this efficacy data in a PA appeal can strengthen the clinical rationale when a first-line agent has not worked.

MassHealth managed care organizations (MCOs), including BMC HealthNet Plan, Tufts Health Together, and Mass General Brigham Health Plan, each maintain their own formularies. Some MCOs may impose step therapy requiring failure of both a benzodiazepine receptor agonist and a sedating antidepressant before authorizing suvorexant. Call the number on the back of the MassHealth card to confirm which MCO manages the member's pharmacy benefit, then verify formulary status directly.

Commercial Insurance Coverage in Massachusetts

Most major commercial plans operating in Massachusetts, including Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, Tufts Health Plan, and Aetna, list Belsomra on their formularies. Tier placement varies. Plans typically slot Belsomra on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), producing copays between $40 and $75 per month.

Step therapy is common. The American Academy of Sleep Medicine (AASM) clinical practice guideline on pharmacologic treatment of chronic insomnia, published in the Journal of Clinical Sleep Medicine (2017), conditionally recommends suvorexant as one option for sleep-onset and sleep-maintenance insomnia [3]. Referencing this guideline in a formulary exception letter signals that the request aligns with specialty society recommendations rather than being an off-formulary convenience choice.

For patients on high-deductible health plans, the effective out-of-pocket cost early in the plan year can mirror full cash pricing until the deductible is met. In these cases, using a discount card or switching to the Merck savings program (discussed below) during the deductible phase may cut costs by 40% to 60% compared to the pharmacy's billed charge.

The Merck Savings Card for Belsomra

Merck offers a manufacturer copay savings card for commercially insured patients. The card reduces out-of-pocket costs to as low as $0 to $40 per fill depending on the specific offer terms, which Merck updates periodically. Patients with commercial insurance, including employer-sponsored and marketplace plans, are eligible.

Key restrictions apply. The Merck savings card does not work for patients covered by Medicare Part D, Medicaid (including MassHealth), TRICARE, or any other federally funded program. This exclusion is a federal Anti-Kickback Statute requirement, not a Merck policy choice. Patients can activate the card at merck's Belsomra savings page or by calling the number printed on the physical card provided in the prescriber's office.

The card typically covers the difference between the patient's copay and a specified floor (often $15 to $40), up to a maximum annual benefit. Once the annual cap is reached, the patient reverts to their plan's standard copay. For a Massachusetts patient on a Tier 3 plan with a $50 copay, the card might reduce each fill to $15, saving $420 over 12 months.

Compounded Suvorexant in Massachusetts

Compounded suvorexant is available through 503A pharmacies licensed in Massachusetts. A 503A pharmacy compounds patient-specific prescriptions based on a valid prescription from a licensed prescriber. This pathway exists for patients who need a dose not commercially available (for instance, 7.5 mg) or who cannot tolerate an inactive ingredient in the manufactured tablet.

Massachusetts regulates compounding pharmacies through the Board of Registration in Pharmacy. After the 2012 New England Compounding Center (NECC) meningitis outbreak originating in Framingham, MA, both state and federal oversight tightened significantly. The Drug Quality and Security Act of 2013 created the 503B outsourcing facility category, but 503A pharmacies remain the primary route for individual patient compounding in Massachusetts.

Compounded suvorexant pricing depends on the pharmacy, the dose, and the formulation. Some patients report prices near or below the average generic price point, while others pay more depending on the compounding pharmacy's cost structure. Because suvorexant is still under patent and commercially available in standard strengths, compounding must comply with the requirement that the prescription identifies a clinical need for the compounded version, such as an allergy to a dye in the commercial tablet or a dose titration not available in manufactured form.

Telehealth Access to Belsomra in Massachusetts

Massachusetts law permits telehealth prescribing of Belsomra. Since suvorexant is a Schedule IV controlled substance, federal DEA regulations (updated in 2023 and extended through the current rulemaking period) allow initial prescribing via audio-video telehealth without a prior in-person visit, provided the prescriber holds a valid Massachusetts controlled substance registration.

This opens access for patients in western Massachusetts, Cape Cod, or the islands who may not live near a sleep medicine specialist. The CDC reports that roughly 14.5% of U.S. adults have difficulty falling asleep most days, and geographic barriers to specialist care compound the problem [4]. Telehealth platforms operating in Massachusetts, including HealthRX, can evaluate patients for insomnia and prescribe suvorexant when clinically appropriate.

One practical note: some telehealth platforms cannot transmit controlled substance prescriptions to all pharmacy systems. Confirm with the telehealth provider that they can e-prescribe Schedule IV medications to your preferred Massachusetts pharmacy before the appointment.

How Suvorexant Compares to Other Insomnia Treatments on Cost

Suvorexant is not the cheapest insomnia medication. Generic zolpidem (Ambien) costs $5 to $15 per month at most Massachusetts pharmacies. Generic trazodone, used off-label for insomnia, costs $4 to $10. These price differences explain why insurers require step therapy before covering Belsomra.

The clinical trade-off matters. Suvorexant works through a different mechanism: it blocks orexin receptors rather than enhancing GABA signaling. The Herring et al. trial in The Lancet Neurology (2014) demonstrated that suvorexant improved wake-after-sleep-onset (WASO) by 29 minutes versus placebo at the 40 mg dose over three months, with lower abuse liability signals compared to traditional hypnotics [2]. For patients who have failed or cannot tolerate Z-drugs or who have a history of substance use disorder, orexin antagonists fill a clinical gap that justifies the higher price.

Lemborexant (Dayvigo), another DORA, entered the market after suvorexant and is priced comparably. A 2020 head-to-head trial (SUNRISE-2, N=949) published in JAMA Network Open compared lemborexant 5 mg and 10 mg against placebo over 12 months and found sustained improvements in sleep onset and maintenance [5]. No direct head-to-head trial between suvorexant and lemborexant has been published. Insurance formulary placement sometimes favors one DORA over the other based on rebate negotiations rather than efficacy data.

Discount Programs and Patient Assistance

Beyond the Merck savings card, several pathways can lower Belsomra costs for Massachusetts residents.

Merck Patient Assistance Program (Merck Helps): Uninsured or underinsured patients earning below 400% of the federal poverty level may qualify for free Belsomra through this program. Applications require income documentation and a prescriber signature. Processing takes two to four weeks.

State Pharmaceutical Assistance: Massachusetts does not operate a standalone state pharmaceutical assistance program (SPAP) for non-elderly adults. Residents age 65 and older or those with disabilities may qualify for MassHealth Standard or CommonHealth, both of which cover Belsomra with PA.

Pharmacy discount cards: GoodRx, RxSaver, and SingleCare aggregate negotiated prices across Massachusetts pharmacies. These are not insurance. They function as a pre-negotiated cash rate. For Belsomra specifically, discount card pricing typically lands between $70 and $95 per month in Massachusetts, roughly matching the state average cash-pay price.

340B pharmacies: Patients receiving care at federally qualified health centers (FQHCs) or certain hospital outpatient departments in Massachusetts may access 340B-discounted pricing. The 340B program requires the prescriber, not the patient, to be affiliated with a covered entity. Prescriptions written by a 340B-eligible provider and filled at a 340B contract pharmacy can cost significantly less. Massachusetts has over 100 FQHC sites across the state.

What Happens When the Belsomra Patent Expires

Merck's composition-of-matter patent on suvorexant is projected to expire around 2029. Once generic suvorexant enters the market, prices should drop substantially, following the pattern seen with other branded sleep medications. Generic zolpidem, for comparison, fell from over $200 per month to under $10 within two years of generic entry.

No Paragraph IV ANDA filings challenging the Belsomra patent have been publicly disclosed as of mid-2026, so generic availability before 2029 appears unlikely. Massachusetts patients paying full price now should focus on the discount strategies outlined above rather than waiting for generics.

The FDA's Orange Book lists the current patent and exclusivity status for suvorexant under NDA 204569 [1].